Cesium chloride (CsCl) is a mineral salt. Cancer patients seeking alternative therapies may consume by mouth or by injection into the body. CsCl can cause decreased potassium level in the blood, which is an important mineral for optimal heart function. On the labelling of some dietary supplements, cesium chloride is a dietary component.
A “novel dietary ingredient” was not for sale in the United States before October 15, 1994, according to current legislation. There is no evidence that cesium chloride was legitimately available for sale as a dietary component in the United States prior to this date, according to the FDA. As a result, cesium chloride is a novel dietary component. And dietary supplements containing it must meet one of the following criteria, among others:
Cesium chloride as Drug
Cesium chloride, as well as all other new dietary ingredients in the product, must be present in the food supply as an article in food in a form that has no alterations chemically. Or there must be a history of use or other evidence of safety establishing that cesium chloride, when used under the conditions recommended or suggested in the product labelling, will reasonably be exempt from adverse effects.
Cesium chloride (CsCl) is a drug that helps to treat a variety of malignancies. Alkalinization of comparatively acidic neoplastic cells is the mechanism of action. CsCl’s effectiveness is yet to be proven in a controlled trial. Seizures, cardiotoxicity, syncope, and mortality has links to the use of CsCl, both orally and intravenously. Despite the fact that intratumoral cancer treatment with numerous antineoplastic drugs is present in the medical literature. There are no examples of intratumoral cancer treatment with CsCl have been discovered.
The patient in this case appears to be the first to develop CsCl poisoning as a result of subcutaneous exposure following an attempted intratumoral injection.
Despite its lack of effectiveness, self-treatment of cancer with cesium chloride continues to have significant side effects. Hypokalemia, which can lead to life-threatening arrhythmia, is one of them. There is no known mechanism for cesium-associated hypokalemia (CAH). In a cancer patient with CAH, we report urinary potassium wasting that responds to amiloride treatment and explore probable causes.
On the basis of the concept known as “high pH cancer therapy,” a complementary alternative medicine technique for cancer treatment, oral consumption of cesium chloride has wide support. However, no adequately verified tumour regression has been recorded to far. Most likely due to the lack of theoretical or experimental support for this hypothesis.
The purpose of this study was to summarize and discuss the current state of knowledge on cesium salts and their medical uses. The existence of cesium in a cell does not imply that its contents will have a high pH. And there is no clinical data to back up assertions that cancer cells are susceptible to cesium. The cesium is a reasonably safe element.
Cesium chloride is popular as a cancer therapy option. It neutralizes the poisonous substance generated by tumour cells, according to supporters, preventing them from proliferating.
These statements does not have the backing of scientific data. Oral cesium can cause diarrhoea, nausea, potassium loss, and irregular pulse. Some alternative medicine practitioners utilize cesium chloride (CsCl) as a cancer therapy. And so, treatment was neither safe nor effective. Chronic usage of CsCl has resulted in serious cardiotoxicity in some people.